retatrutide trial weight loss Lilly's triple agonist achieves 16.8% in phase 3 Triple hormone receptor agonist retatrutide

[Google Scholar] 57.Almandoz J.P., Wadden T.A., Tewksbury C., Apovian C.M., Fitch A., Ard J.D., Li Z., Richards J., Butsch W.S., Jouravskaya I., et al

They also believe GLP-1 coverage would enhance employees' health and perception of healthcare benefits: 79% agree that GLP-1 coverage will help employees' health long term 77% agree that GLP-1 coverage would make employees feel they get a better health insurance package What employers already covering GLP-1s have to say Companies already covering GLP-1s (25%) say they plan to continue covering them (99%), providing perspective on balancing financial impact with employee engagement and satisfaction

GLP-1RAs have demonstrated significant anti-colorectal cancer activity [46], with the protective effects increasing in a duration-dependent manner

It may interact with certain medications and isn't recommended during pregnancy or breastfeeding, as its effects aren't fully understood

Retatrutide Research Objective The objective of this clinical research was to evaluate the safety, tolerability, and efficacy of retatrutide in reducing body weight and improving metabolic markers in adults with obesity or overweight

10.1124/pr.55.1.6